The Director, Pricing and Market Access Strategy Lead (PASL) for Immunology will lead the Global Market Access strategy for admilparant across international markets. Admilparant is a potential first-in-class oral LPA1 antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Following positive Phase 3 ALOFT-IPF results, the asset is moving toward regulatory submissions, with topline results from the fully enrolled ALOFT-PPF trial expected in early 2027. The role will shape the asset’s access strategy, evidence generation, and key development and commercialization decisions as it moves toward potential launch. Reporting to the Executive Director, GMAx Global Launch Strategy for Cardiovascular and Immunology, the Director will serve as the Market Access representative on the Global Product Team. The role partners across Commercial, Medical, Regulatory, Clinical, Advocacy, Policy, Business Insights and Analytics, HEOR, and markets worldwide, and contributes to market access and pricing governance. The successful candidate will bring deep global pricing and market access expertise, sound strategic judgment, and the ability to influence senior leaders and collaborate inclusively across functions and geographies.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director